Matches in SemOpenAlex for { <https://semopenalex.org/work/W3110419483> ?p ?o ?g. }
- W3110419483 endingPage "114866" @default.
- W3110419483 startingPage "114866" @default.
- W3110419483 abstract "A cyclodextrin complex of afatinib, a FDA-approved pan–ErbB inhibitor and known P-gp substrate, was developed to enhance its bio-activity while also reducing p-glycoprotein (P-gp) efflux, thereby improving its transport across the intestinal membrane. A sulfobutyl ether derivative of β-cyclodextrin (SBE-β-CD, pharmaceutical grade) was selected based on preliminary phase solubility studies and molecular modeling to prepare an afatinib-cyclodextrin inclusion complex. Various solid-state characterization studies were performed to confirm complex formation and to evaluate its physicochemical properties. Results showed that complexation with SBE-β-CD enhanced afatinib's stability in PBS (pH 7.4), as well as in simulated gastric (pH 2.0) and intestinal fluids (pH 6.5). In addition, the cytotoxicity (reduced IC50 after complexation across multiple cancer cell lines with varied P-gp expression) and tumor volume retraction ability (in-vitro 3D-spheroids of P-gp overexpressing cell lines) of afatinib were both enhanced through cyclodextrin complexation. CD complexation effect of afatinib on P-gp efflux as well as transport was assessed using in-vitro permeability studies (Caco-2 and EpiIntestinal® tissue models). Results demonstrated that cyclodextrin complexation significantly increased the transport of afatinib across the gut membrane while also reducing its efflux ratio, indicating its vital role in P-gp efflux modulation." @default.
- W3110419483 created "2020-12-07" @default.
- W3110419483 creator A5000476704 @default.
- W3110419483 creator A5028815618 @default.
- W3110419483 creator A5033035004 @default.
- W3110419483 creator A5039112637 @default.
- W3110419483 creator A5044867727 @default.
- W3110419483 creator A5054635249 @default.
- W3110419483 creator A5064790610 @default.
- W3110419483 creator A5080537464 @default.
- W3110419483 creator A5081077625 @default.
- W3110419483 creator A5082282921 @default.
- W3110419483 date "2021-04-01" @default.
- W3110419483 modified "2023-10-16" @default.
- W3110419483 title "Bypassing P-glycoprotein mediated efflux of afatinib by cyclodextrin complexation – Evaluation of intestinal absorption and anti-cancer activity" @default.
- W3110419483 cites W1174101784 @default.
- W3110419483 cites W1202292658 @default.
- W3110419483 cites W1636530151 @default.
- W3110419483 cites W1965857736 @default.
- W3110419483 cites W1970711990 @default.
- W3110419483 cites W1970807670 @default.
- W3110419483 cites W2002906517 @default.
- W3110419483 cites W2007859813 @default.
- W3110419483 cites W2010813821 @default.
- W3110419483 cites W2012992007 @default.
- W3110419483 cites W2019102162 @default.
- W3110419483 cites W2048084632 @default.
- W3110419483 cites W2053652959 @default.
- W3110419483 cites W2064788032 @default.
- W3110419483 cites W2070332894 @default.
- W3110419483 cites W2078825674 @default.
- W3110419483 cites W2082072659 @default.
- W3110419483 cites W2093932026 @default.
- W3110419483 cites W2097781997 @default.
- W3110419483 cites W2098094886 @default.
- W3110419483 cites W2106315777 @default.
- W3110419483 cites W2112331150 @default.
- W3110419483 cites W2126196039 @default.
- W3110419483 cites W2137930631 @default.
- W3110419483 cites W2142024216 @default.
- W3110419483 cites W2152368724 @default.
- W3110419483 cites W2156126361 @default.
- W3110419483 cites W2157610502 @default.
- W3110419483 cites W2171157655 @default.
- W3110419483 cites W2271612480 @default.
- W3110419483 cites W2321491843 @default.
- W3110419483 cites W2461071277 @default.
- W3110419483 cites W2484071785 @default.
- W3110419483 cites W2512058578 @default.
- W3110419483 cites W2593198694 @default.
- W3110419483 cites W2609745943 @default.
- W3110419483 cites W2612323044 @default.
- W3110419483 cites W2766576331 @default.
- W3110419483 cites W2775048446 @default.
- W3110419483 cites W2786504480 @default.
- W3110419483 cites W2793785550 @default.
- W3110419483 cites W2794458190 @default.
- W3110419483 cites W2800612483 @default.
- W3110419483 cites W2804041574 @default.
- W3110419483 cites W2895772659 @default.
- W3110419483 cites W2896745762 @default.
- W3110419483 cites W2898119015 @default.
- W3110419483 cites W2911358073 @default.
- W3110419483 cites W2912720741 @default.
- W3110419483 cites W2941125651 @default.
- W3110419483 cites W2960762304 @default.
- W3110419483 cites W2969579757 @default.
- W3110419483 cites W2976012718 @default.
- W3110419483 cites W2990075145 @default.
- W3110419483 cites W2991205275 @default.
- W3110419483 cites W3010294138 @default.
- W3110419483 cites W3011154122 @default.
- W3110419483 cites W3022737383 @default.
- W3110419483 cites W3027132000 @default.
- W3110419483 cites W3031317685 @default.
- W3110419483 cites W3033667635 @default.
- W3110419483 cites W3038540512 @default.
- W3110419483 cites W3042493876 @default.
- W3110419483 cites W3046849079 @default.
- W3110419483 cites W3082127291 @default.
- W3110419483 cites W4247852925 @default.
- W3110419483 doi "https://doi.org/10.1016/j.molliq.2020.114866" @default.
- W3110419483 hasPublicationYear "2021" @default.
- W3110419483 type Work @default.
- W3110419483 sameAs 3110419483 @default.
- W3110419483 citedByCount "10" @default.
- W3110419483 countsByYear W31104194832021 @default.
- W3110419483 countsByYear W31104194832022 @default.
- W3110419483 countsByYear W31104194832023 @default.
- W3110419483 crossrefType "journal-article" @default.
- W3110419483 hasAuthorship W3110419483A5000476704 @default.
- W3110419483 hasAuthorship W3110419483A5028815618 @default.
- W3110419483 hasAuthorship W3110419483A5033035004 @default.
- W3110419483 hasAuthorship W3110419483A5039112637 @default.
- W3110419483 hasAuthorship W3110419483A5044867727 @default.
- W3110419483 hasAuthorship W3110419483A5054635249 @default.
- W3110419483 hasAuthorship W3110419483A5064790610 @default.
- W3110419483 hasAuthorship W3110419483A5080537464 @default.